What is HC Wainwright’s Estimate for Kyntra Bio Q1 Earnings?

Kyntra Bio Inc (NASDAQ:KYNB) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Kyntra Bio in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst M. Keller expects that the company will post earnings of ($3.85) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Kyntra Bio’s Q2 2026 earnings at ($3.87) EPS, Q3 2026 earnings at ($4.00) EPS, Q4 2026 earnings at ($4.09) EPS, FY2026 earnings at ($15.80) EPS, FY2027 earnings at ($8.96) EPS and FY2028 earnings at ($8.89) EPS.

A number of other analysts have also commented on the stock. Zacks Research lowered shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Weiss Ratings initiated coverage on Kyntra Bio in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Kyntra Bio Stock Performance

KYNB opened at $7.30 on Thursday. The business’s 50 day simple moving average is $7.75. Kyntra Bio has a fifty-two week low of $4.85 and a fifty-two week high of $12.60. The company has a market capitalization of $29.57 million, a P/E ratio of 0.16 and a beta of 0.84.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.